


# High prevalence of epilepsy in onchocerciasis endemic regions in the Democratic Republic of the Congo


R Colebunders<sup>1</sup>, F Tepage<sup>2</sup>, M Mandro<sup>3</sup>, J Mokili<sup>4</sup>, K Pfarr<sup>5</sup>, JM Kashama<sup>6</sup>,  
B Levick<sup>7</sup>, D Rossy<sup>3</sup>, A Tagoto<sup>8</sup>, A Laudisoit<sup>1,7</sup>

1. Global Health Institute, University of Antwerp, Belgium
2. National Onchocerciasis control program, DRC
3. Ministry of Health, Ituri Province, DRC
4. San Diego State University
5. University hospital of Bonn
6. Neuropsychopathologic Centre, University of Kinshasa, DRC
7. University of Liverpool, UK
8. University of Kisangani, DRC

# Increase of epilepsy prevalence with increased onchocerciasis prevalence




# Rapid epidemiological mapping of onchocerciasis (REMO map, 2008)




# Methods

- Study period: 2014-16
- Studies in Bas-Uélé, Tshopo and Ituri province
- Epilepsy prevalence surveys in 33 villages
- 3 case control studies

# Study sites




# Epilepsy studies in Titule




- 67/2,908 people (2.3%) with epilepsy
- Mainly convulsive epilepsy
- Living close to the river was a risk factor

Epilepsy prevalence in non-onchocerciasis endemic demographic surveillance sites in South Africa, Kenya, Uganda: 0.23% (Kariuki et al)

# Titule: age at the onset of the epilepsy



# Prevalence of convulsive epilepsy and age at onset in non-onchocerciasis areas in Africa





# TITULE : case control study

Characteristics	Cases	Controls	OR (95% CI)	P-value
Mean body weight, Kg (SD)	38.9 (11.2) (n=58)	46.7 (15.2) (n=23)	0.96 (0.91 – 1.00)	0.06
Mean height, cm (SD)	148 (15) (n=58)	154 (18) (n=22)	0.98 (0.94 – 1.02)	0.4
Onchocerciasis skin lesions	12/41 (29%)	1/56 (4%)	10.32 (2.04 – 52.26)	0.005
Itching	26/40 (65%)	8/51 (16%)	11.22 (3.83 – 32.82)	<0.001
Skin nodules	3/40 (8%)	2/46 (4%)	1.13 (0.14 – 9.29)	0.9
Burn scars	10/57 (18%)	0/61 (0%)	<sup>d</sup>	0.001

# TITULE: case control study

Characteristics	Cases	Controls	P-value
Skin snip OV PCR pos	26/34 (76%)	10/14 (71%)	0.7
OV16 pos	39/49 (78%)	15/18 (83%)	0.5
<i>Mansonella perstans</i> PCR pos blood	39/49 (78%)	13/20 (65%)	0.91
<i>Loa Loa</i>	1	1	0.91
<i>Taenia solium</i> AB	neg	neg	
<i>Toxocara</i> AB	neg	neg	
<i>Trypanosoma</i> sp AB	neg	neg	
Ivermectin use last round	29/59 (49%)	29/61 (48%)	0.8

# Ituri: case control study

	Persons with epilepsy		Controls	
	Drazu	Rassia	Drazu	Rassia
Number of years IVM	0	3	0	3
Biopsy pos (MF)	55.9%	50%	29%	12.5%
Mean MFL	33.6	21.5	3.8	2.7
OV16 pos	45.7%	45.8%	26.0%	18.7%

## 2016 epilepsy prevalence in door to door surveys in Ituri an onchocerciasis endemic region in the DRC

Province	Health zone	Health Area	Epilepsy prevalence (%)
Ituri	Logo	Draju	6.2%
	Rethy	Rassia	3.6%
		Lokpa	3.7%

# Stunted growth (“Nakalanga syndrome”)

**26 year old, 26kg, 1m27, Salambongo, DRC**



**24 year old, Mvolo, South Sudan**



# Mean age of onset of epilepsy

- OAE DRC: 11 year<sup>1</sup>
- Nodding syndrome (atonic form of epilepsy)  
Uganda: 7.6 year<sup>2</sup>
- Nakalanga syndrome: 2-3 year<sup>3</sup>

51 year old person, onset of epilepsy 3 years ago, migrated into the area 5 years ago, OV16 and skin test microfilariae positive, never took ivermectin



# OAE can be prevented by increasing ivermectin coverage



- In northern Uganda the nodding syndrome epidemic stopped after implementing onchocerciasis control
- In Cameroon/Tanzania the incidence of epilepsy also seems to have decreased since CDTi




# Urgent need to prevent OAE



November 2013, Mvolo,  
Western Equatoria State, South  
Sudan

- 1 in 6 children with epilepsy
- At least 50% of families at least one child with epilepsy

# It requires several years of exposure to *Onchocerca volvulus* to develop OAE



# Conclusion

- High prevalence of epilepsy in onchocerciasis endemic regions in the DRC
- 3 types of clinical presentation of OAE: nodding syndrome, Nakalanga syndrome and other forms of epilepsy (mainly generalized tonic-clonic seizures)
- Increasing CDTi geographic and therapeutic coverage may decrease the incidence of OAE
- More advocacy is needed to improve treatment/care of patient with epilepsy in Africa



SAN DIEGO STATE  
UNIVERSITY

